Explore Cell Therapy

14 - HCT Across MDS Genetic Subtypes, Part I: Expanding Access to Older Patients

32 min · 14 jan 2025
aflevering 14 - HCT Across MDS Genetic Subtypes, Part I: Expanding Access to Older Patients cover

Beschrijving

In this two-part "Explore Cell Therapy" podcast episode, Coleman Lindsley, MD, PhD, and Corey Cutler, MD, MPH, FRCP(C), discuss recent and evolving research supporting the broad benefits of hematopoietic cell transplant (HCT) across all genetic subtypes of myelodysplastic syndrome (MDS), including for patients with high-risk mutations like TP53. In Part I: Expanding Access to Older Patients, guests explore major advances in transplant for older patients with MDS, highlighting the recent expansion of coverage through the Centers for Medicare and Medicaid Services (CMS), a significant milestone driven by recent studies that demonstrate the safety and efficacy of HCT in patients over 65 years old. To read bios on the panelists and to access additional resources related to this episode, visit Our Site [https://www2.bethematchclinical.org/l/566592/2023-06-12/n41tmn].

Reacties

0

Wees de eerste die een reactie plaatst

Meld je nu aan en word lid van de Explore Cell Therapy community!

Begin hier

2 maanden voor € 1

Daarna € 9,99 / maand · Elk moment opzegbaar.

  • Podcasts die je alleen op Podimo hoort
  • 20 uur luisterboeken / maand
  • Gratis podcasts

Alle afleveringen

36 afleveringen

aflevering 14 - HCT Across MDS Genetic Subtypes, Part I: Expanding Access to Older Patients artwork

14 - HCT Across MDS Genetic Subtypes, Part I: Expanding Access to Older Patients

In this two-part "Explore Cell Therapy" podcast episode, Coleman Lindsley, MD, PhD, and Corey Cutler, MD, MPH, FRCP(C), discuss recent and evolving research supporting the broad benefits of hematopoietic cell transplant (HCT) across all genetic subtypes of myelodysplastic syndrome (MDS), including for patients with high-risk mutations like TP53. In Part I: Expanding Access to Older Patients, guests explore major advances in transplant for older patients with MDS, highlighting the recent expansion of coverage through the Centers for Medicare and Medicaid Services (CMS), a significant milestone driven by recent studies that demonstrate the safety and efficacy of HCT in patients over 65 years old. To read bios on the panelists and to access additional resources related to this episode, visit Our Site [https://www2.bethematchclinical.org/l/566592/2023-06-12/n41tmn].

14 jan 202532 min
aflevering 14 - HCT Across MDS Genetic Subtypes, Part II: The Role of Genetics and Early Consult artwork

14 - HCT Across MDS Genetic Subtypes, Part II: The Role of Genetics and Early Consult

In this two-part "Explore Cell Therapy" podcast episode, Coleman Lindsley, MD, PhD, and Corey Cutler, MD, MPH, FRCP(C), discuss recent and evolving research supporting the broad benefits of hematopoietic cell transplant (HCT) across all genetic subtypes of myelodysplastic syndrome (MDS), including for patients with high-risk mutations like TP53.  In Part II, experts stress the importance of early consultation to optimize treatment decisions and ensure equity in access to HCT for older patients in need of a curative treatment option.    To read bios on the panelists and to access additional resources related to this episode, visit Our Site [https://www2.bethematchclinical.org/l/566592/2023-06-12/n41tmn].

14 jan 202531 min
aflevering 13 - Optimizing Donor Searches in HCT, Part II: Overcoming Barriers artwork

13 - Optimizing Donor Searches in HCT, Part II: Overcoming Barriers

This two-part “Explore Cell Therapy” podcast episode dives into recent research on the benefits and challenges of optimizing donor searches for allogeneic hematopoietic cell transplant (HCT). Joseph Pidala, MD, PhD, Moffitt Cancer Center, and Jason Dehn, MPH, NMDPSM, review crucial findings from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 1702 trial to shed light on the pivotal role of search prognosis in helping more eligible patients receive HCT.   In Part II: Overcoming Barriers, the experts review implications for the future of donor search optimization, transplant access and health equity in an increasingly diverse patient population.  To read bios on the panelists and to access additional resources related to this episode, visit Our Site [https://www2.bethematchclinical.org/l/566592/2023-06-12/n41tmn].

20 nov 202426 min
aflevering 13 - Optimizing Donor Searches in HCT, Part I: Strategies and Considerations artwork

13 - Optimizing Donor Searches in HCT, Part I: Strategies and Considerations

This two-part “Explore Cell Therapy” podcast episode dives into recent research on the benefits and challenges of optimizing donor searches for allogeneic hematopoietic cell transplant (HCT). Joseph Pidala, MD, PhD, Moffitt Cancer Center, and Jason Dehn, MPH, NMDPSM, review crucial findings from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 1702 trial to shed light on the pivotal role of search prognosis in helping more eligible patients receive HCT.   In Part I: Strategies and Considerations, the experts discuss strategies to prioritize alternative donor sources to ensure that more patients receive HCT at optimal timepoints.  To read bios on the panelists and to access additional resources related to this episode, visit Our Site [https://www2.bethematchclinical.org/l/566592/2023-06-12/n41tmn].

20 nov 202425 min